Comparing three adjuvant chemotherapy regimes after modified radical mastectomy in breast cancer patients using log-logistic model

Koomesh

Volumn 11, Issue 4, 2010, Pages 279-287

  Faradmal, Javad ^a   Kazemnejad, Anoshirvan ^a   Bakhshi, Reza Khoda ^b   Hajizadeh, Ebrahim ^a   Gohari, Mahmood Reza ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b Fayyazbakhsh Hospital   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adjuvant chemotherapy; Breast cancer; Disease free time; Log logistic model; Survival analysis

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; OVERALL SURVIVAL; STATISTICAL MODEL; TUMOR VOLUME;

EID: 77952942168     PISSN: 16087046     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Cancer office of center for disease control and prevention. Iranian annual of national cancer registration report 2005-2006. Tehran: Ministry of Health and Medical Education of IR Iran; 2007. (Persian) Available from: http://www.emro.who.int/ncd/pdf/cancer-registry-iran.pdf [cited 2010 Apr 5a]
2. Cox JD, Ang KK. Radiation Oncology: Rationale, Technique, Results. 9th ed. Philadelphia: Mosby Inc.; 2009.
3. DeVita VT, Lawrence TS, Rosenberg SA. Cancer: Principles & Practice of Oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
4. Kadivar M. and Bozorgmehr N. Study of cytologic grading of samples obtained from breast carcinoma cases referred to Milad and Rasoul-e-Akram hospital between 2004 and 2005. J Iran Uni Med Sci 2007; 54: 129-138 (Persian).
5. Early breast cancer trialists' collaborative group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351:1451-1467.
6. Bakhtyari A. and Hajyan K. Five year disease-free survival rate in breast cancer patients in Rajaii Hospital, Babolsar. Journal of school of public health and institute of public research. 2007; 5: 53-60 (Persian).
7. Khosravi Shahi P, Izarzugaza Perón Y, Encinas García S, Díaz Muñoz de la Espada VM. and Pérez Manga G. Adjuvant treatment of operable breast cancer. An Med Interna 2008; 25: 36-40. (Pubitemid 351520796)
8. Fazl-Ali Zadeh A. and Hatami E. Study of impact of reducing radiotherapy duration after mastectomy on rate of recurrence in breast cancer patients. Pajohandeh 2004; 9: 209-214 (Persian).
9. Kuru B, Camlibel M, Dinc S, Gulcelik MA, Atalay C. and Alagol H. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer. J Exp Clin Cancer Res 2005; 24: 363-372. (Pubitemid 41416120)
10. Harbeck N. Adjuvant chemotherapy in primary breast cancer. Onkologie 2003; 26: 17-20. (Pubitemid 38067667)
11. Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B. and et al. Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer. J Clin Oncol 2010; 28: 77-82.
12. Campone M, Fumoleau P, Bourbouloux E, Kerbrat P. and Roché H. Taxanes in adjuvant breast cancer setting: which standard in Europe? Crit Rev Oncol Hematol 2005; 55: 167-175.
13. Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M. and et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008; 100: 121-133.
14. Geisler DP, Boyle MJ, Malnar KF, Melichar RM, McGee JM, Nolen MG. and Broughan TA. Adjuvant radiation after modified radical mastectomy for breast cancer fails to prolong survival. Am Surg 2000; 66: 458-459.
15. Kimura M, Tominaga T, Takatsuka Y, Toi M, Abe R, Koyama H. and et al. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with nodepositive breast cancer in Japan. Breast Cancer 2009.
16. Livi L, Saieva C, Borghesi S, De Luca Cardillo C, Scotti V, Mangoni M. and et al. Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer. J Chemother 2009; 21: 558-565.
17. Olivotto IA, Bajdik CD, Plenderleith IH, Coppin CM, Gelmon KA, Jackson SM. and et al. Adjuvant Systemic Therapy and Survival after Breast Cancer. N Engl J Med1994; 330: 805-810.
18. Sledge GW Jr. Is HER-2/neu a predictor of anthracycline utility? No. J Natl Cancer Inst Monogr 2001; 30: 85-87.
19. Hayes D, Thor A, Dressler L, Weaver D, Edgerton S, Cowan D. and et al. HER2 and response to paclitaxel in nodepositive breast cancer. N Engl J Med 2007; 357: 1496-1506.
20. Mamounas E, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek S, Fisher B. and et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23: 3686-3696.
21. American Joint Committee on Cancer AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.
22. Le Doussal V, Tubiana-Hulin M, Freidmans S, Hacene K, Spyratos F. and Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson. An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989; 64: 1914-1921.
23. Klein JP. and Moeschberger ML. Survival analysis: Techniques for censored and truncated data. New York: Springer; 1997.
24. Kleinbaum DG, Klein M. Survival analysis: A self learning text. 2ed ed. New York: Springer; 2005.
25. Royston P. The lognormal distribution as a model for survival time in cancer, with an emphasis on prognostic factors. Stat Neerl 2001; 55: 89-104. (Pubitemid 33226085)
26. López-Tarruella S. and Martín M. Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Res 2009; 11: 204.
27. Touboul E, Buffat L, Belkacémi Y, Lefranc JP, Uzan S, Lhuillier P. and et al. Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys 2000; 46: 683-684
28. Crown J, O'Leary M. and Ooi WS. Docetaxel and Paclitaxel in treatment of breast cancer: A review of clinical experience. Oncologist 2004; 9: 24-32. (Pubitemid 38747840)